Phagenyx™
Treat dysphagia, restore control

A revolution in dysphagia treatment
Phagenyx™ is the first dysphagia therapy clinically proven to improve swallow function by restoring neurological control. Dysphagia significantly increases the risk of stroke patients developing life-threatening pneumonia and can also lead to malnutrition and a poor quality of life. Phagenyx™ offers a unique opportunity to treat the cause of dysphagia, thereby reducing the risk of complications and associated healthcare costs and improving outcomes.

**Treating the cause of dysphagia**

**The Problem**

*After a stroke, every day with dysphagia is a day with risk*

Dysphagia occurs in 30 to 78% of adult patients with an acute stroke. Dysphagia and aspiration are closely associated, and increase the risk of developing pneumonia 3-fold and 4.5-fold, respectively. Aspiration pneumonia occurs in 13 to 19% of dysphagic stroke patients.

<table>
<thead>
<tr>
<th>Cost of hospitalisation after stroke</th>
<th>Cost ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without pneumonia</td>
<td>6,206</td>
</tr>
<tr>
<td>With pneumonia</td>
<td>21,043</td>
</tr>
</tbody>
</table>

Length of hospital stay is significantly extended by dysphagia. Dysphagia following stroke is an independent predictor of institutionalisation or subsequent hospital readmission. Depression is strongly and independently associated with dysphagia. Dysphagia increases risk of early death. Dietary texture modification and compensatory strategies may help reduce the risk but don’t treat the underlying cause. Gastrostomy feeding can be costly and is associated with numerous complications. Tube feeding does not protect against the development of respiratory infections.
**The Treatment**

Phagenyx™ treats the cause of dysphagia

- Research showed that swallowing control is bi-hemispheric but that one hemisphere dominates control.24
- Phagenyx™ precisely delivers controlled stimulation to the nerve clusters linked to the muscle groups involved in swallowing.
- The stimulation travels along nerve pathways to the swallowing control centres in the brain.
- This focused stimulation selectively increases brain activity and results in rapid and functionally relevant improvements in swallowing safety.

**The Benefit**

Phagenyx™ offers a unique opportunity to reduce the costs and complications associated with dysphagia

- Median (95% confidence interval) length of hospital stay was 21 days (18-24 days) after pharyngeal stimulation and 26 days (21-31 days) after sham stimulation.

Using Phagenyx™ when patients present with dysphagia will potentially:

- Enable patients to swallow safely, improving nutritional status and promoting more independent feeding.25
- Reduce length of stay, enabling earlier discharge.25
- Reduce risk of aspiration, helping to avoid pneumonia.25,26
- Reduce healthcare costs.
- Lead to a reduction in mortality risks associated with dysphagia after stroke.
- Improve quality of life.
A revolution in dysphagia treatment

References